IceCure's Advanced Multiprobe Cryoablation Technology Receives Patent Approval in Japan
November 25, 2024 - 22:01
IceCure Medical Ltd. has announced that its next-generation multiprobe cryoablation technology has received a Notice of Allowance from Japan's Patent Office. This significant development marks a key milestone for the company's innovative approach to minimally invasive medical procedures.
The multiprobe cryoablation technology is designed to enhance the effectiveness and efficiency of cryoablation treatments, which are used to destroy abnormal tissues through extreme cold. This advancement is expected to provide physicians with improved tools for treating various medical conditions, potentially leading to better patient outcomes.
The approval from Japan's Patent Office underscores the technological advancements that IceCure is bringing to the field of cryoablation, positioning the company for growth in the competitive medical technology market.
MORE NEWS
April 22, 2026 - 12:12
Japan lowers restrictions on weapon and technology exportsIn a historic policy shift, the Japanese government has approved a sweeping revision to its strict defense export controls, effectively lifting a decades-long ban on selling lethal weapons abroad....
April 21, 2026 - 17:12
Technology Guide: Modern cellular analysis in early drug discoveryThe initial stages of drug discovery are being transformed by a new generation of cellular analysis technologies. By moving beyond traditional, one-dimensional assays, scientists are now able to...
April 21, 2026 - 04:09
New technology could help Nancy Guthrie case: GenealogistA leading forensic genealogist has announced that emerging DNA technology could finally unlock the mystery surrounding Nancy Guthrie, a case that has remained cold for over three decades. The...
April 20, 2026 - 19:27
Navigating the AI Regulatory Maze: Experts Weigh In on Innovation and PolicyThe rapid advancement of artificial intelligence has sparked a complex global debate on how best to govern the technology. According to analysts Anna Viñals Musquera and Scott Babwah Brennen, a...